# Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

> **NCT04526795** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent T-Cell Prolymphocytic Leukemia
- Refractory Acute Biphenotypic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory T-Cell Prolymphocytic Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Fludarabine
- **DRUG:** Pegcrisantaspase

## Key facts

- **NCT ID:** NCT04526795
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-09
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Administratively Complete
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526795, "Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04526795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*